The purpose of our research is the investigation of multimodal treatment in adult patients with neoplastic disease in collaboration with other member institutions in the CALGB. Walter Reed Army Medical Center (WRAMC) has been an active member of CALGB for 24 years. WRAMC's participation was initially guided by Dr. Johannes Blom. With his retirement in 1979, WRAMC's participation lagged scientifically and administratively. With the arrival of Dr. Raymond B. Weiss as a new scientific director for WRAMC's cancer research efforts, all aspects of participation in the CALGB by WRAMC have markedly increased. The quality of data collection has gone from low to the equal of any other group member with the hiring of Ms. Carolyn Bailey. With Dr. Weiss having ad previous experience in CALG and 3 years' stint at NCI, he was able to generate enthusiasm among the young WRAMC staff. Accrual to group protocols has significantly increased to a level of some 90 patients/year, and WRAMC's accrual in relation to the rest of the CALGB has increased. Dr. Weiss is chariman of the Data Audit Committee and is directing the auditing process mandated by NCI. Dr. Perry and Ms. Bailey are members of this committee. Drs. Booth and Weiss have authored 2 phase II studies in breast cancer (#8341-Acivicin and #8242-Carboplatin). Dr. Terebelo is chairman of protocol #8173 for relapsed ALL, a study that grew out of pilot data generated in part at WRAMC. WRAMC has been a major contributor to the Testicular cancer Intergroup Study under the direction of Dr. Taylor and Ms. Bailey. Dr. Weiss is a member of the Breast Cancer and Chemotherapy Core Committees and also a member of the Testicula Study Executive Committee. Dr. Weiss has a particular interest and expertise in Phase I and II studies and has generated 5 such studies at WRAMC outside CALGB. Dr. Diehl is a member of Lymphoma Committee and is co-author of a proposed Hodgkin's disease study of advanced stages with bulky tumor masses. With a new degree of enthusiasm for participation in CALGB, quality data collection, scientific ferment in doing Phase I and iI studies, leadership in the CALGB administrative structure, higher levels of accrual, and participation at group meetings, the investigators at WRAMC plan to maintain a high level of visible participation in CALGB. This effort by WRAMC will add to CALGB's overall accrual and scientific endeavors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA026806-07
Application #
3556844
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1979-12-01
Project End
1988-03-31
Budget Start
1986-04-01
Budget End
1987-03-31
Support Year
7
Fiscal Year
1986
Total Cost
Indirect Cost
Name
U.S. Walter Reed Army Med Center
Department
Type
DUNS #
City
Washington
State
DC
Country
United States
Zip Code
20307
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Metzeler, K H; Maharry, K; Kohlschmidt, J et al. (2013) A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia 27:2023-31
Boylan, Alice M; Wang, Xiaofei F; Ko, Richard et al. (2013) Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902. J Thorac Cardiovasc Surg 146:206-11
Grant, Barbara W; Jung, Sin-Ho; Johnson, Jeffrey L et al. (2013) A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer 119:3797-804
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8

Showing the most recent 10 out of 86 publications